POSSIBILITIES FOR REDUCING THE RISK OF PRETERM BIRTH IN THE CONTEXT OF EVIDENCE-BASED MEDICINE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The paper analyzes some aspects of the etiopathogenesis of preterm birth, which are associated with the inadequate biological effects of progesterone. It gives current evidence for the use of progestagens for pregravid preparation and pregnancy support and discusses criteria for choosing progestagens.

全文:

受限制的访问

作者简介

Sergey Aganezov

I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia; I.P. Pavlov First Saint Petersburg State Medical University

Email: aganezov@mail.ru
PhD, Associate Professor, Department of Obstetrics and Gynecology; Assistant of the Department of Obstetrics and Gynecology 191015, Russia, St. Petersburg, Kirochnaya str. 41

Natalia Aganezova

I.I. Mechnikov North-West State Medical University, Ministry of Health of Russia

Email: aganezova@mail.ru
MD, Associate Professor, Department of Obstetrics and Gynecology 191015, Russia, St. Petersburg, Kirochnaya str. 41

参考

  1. Menon R. Preterm birth: a global burden on maternal and child health. Pathog. Glob. Health. 2012; 106(3): 139-40.
  2. World Association of Perinatal Medicine (WAPM). Recommendations and Guidelines for Perinatal Medicine. 2007.
  3. Приказ Минздравсоцразвития России №1687н от 27 декабря 2011г. «О медицинских критериях рождения, форме документа о рождении и порядке ее выдачи».
  4. Подзолкова Н.М., Глазкова О.Л. Симптом. Синдром. Диагноз. Дифференциальная диагностика в гинекологии. 3-е изд. М.: ГЭОТАР- Медиа; 2014. 736 с.
  5. Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil. Steril. 2012; 98(5): 1112-7. doi: 10.1016/j.fertnstert.2012.06.050.
  6. Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil. Steril. 2008; 89(4): 789-92.
  7. King R.J., Whitehead M.I. Assessment of the potency of orally administered Progestins in women. Fertil. Steril. 1986; 46(6): 1062-6.
  8. Van der Linden M., Buckingham K., Farquhar C., Kremer J.A.M., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 2011; (10): CD009154. doi: 10.1002/14651858.CD009154.pub2v.
  9. Van der Linden M., Buckingham K., Farquhar C., Kremer J.A.M., Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst. Rev. 2012; (7).
  10. Радзинский В.Е., Оразмурадов А.А., ред. Ранние сроки беременности. 2-е изд. М.: Status Praesens; 2009. 480 с.
  11. Александрова Н.В., Баев О.Р. Ранние этапы становления системы мать-плацента-плод. Акушерство и гинекология. 2011; 8: 4-10.
  12. Zainul Rashid M.R., Lim J.F., Nawawi N.H., Luqman M., Zolkeplai M.F., Rangkuty H.S. et al. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in primigravidae. Gynecol. Endocrinol. 2014; 30(3): 217-20.
  13. Szekeres-Bartho J., Barakonyi A., Par G., Polgar B., Palkovics T., Szereday L. Progesterone as an immunomodulatory molecule. Int. Immunopharmacol. 2001; 1(6): 1037-48.
  14. Stygar D., Wang H., Vladic Y.S., Ekman G., Eriksson H., Sahlin L. Increased level of matrix metalloproteinases 2 and 9 in the ripening process of the human cervix. Biol. Reprod. 2002; 67(3): 889-94.
  15. Кузьмин В.Н., Мурриева Г.А. Роль неспецифических урогенитальных инфекций в патогенезе самопроизвольных преждевременных родов. Лечащий врач. 2013; 6: 60-2.
  16. Kalinka J., Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am. J. Reprod. Immunol. 2005; 53(4): 166-71.
  17. Saraswat L., Bhattacharya S., Maheshwari A., Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. Br. J. Obstet. Gynaecol. 2010; 117(3): 245-57.
  18. Polgar B., Nagy E., Miko E., Varga P., Szekeres-Bartho J. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol. Reprod. 2004; 71(5): 1699-705.
  19. Wahabi H.A., Fayed A.A., Esmaeil S.A., Al Zeidan R.A. Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. 2011; (12): CD005943.
  20. Gerhard I., Gwinner B., Eggert-Kruse W., Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biol. Res. Pregnancy Perinatol. 1987; 8(1 1ST Half): 26-34.
  21. Palagiano A., Bulletti C., Pace M.C., DE Ziegler D., Cicinelli E., Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann. N. Y. Acad. Sci. 2004; 1034: 200-10.
  22. El-Zibdeh M.Y., Yousef L.T. Dydrogesterone support in threatened miscarriage. Maturitas. 2009; 65(1): 43-6.
  23. Pandian R.U. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009; 65(Suppl. 1): S47-50.
  24. Wahabi H.A., AbedAlthagafi N.F., Elawad M. Progestogen for treating threatened miscarriage. Cochrane Database Syst. Rev. 2007; (3): CD005943.
  25. Romero R., Yeo L., Miranda J., Hassan S.S., Conde-Agudelo A., Chaiworapongsa T. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J. Perinat. Med. 2013; 41(1): 27-44.
  26. Хофмейр Д.Ю., Нейлсон Д.П., Алфиревич З. и др. Кохрановское руководство «Беременность и роды»: пер. с англ. Сухих Г.Т., ред. М.: Логосфера; 2010: 161.
  27. Hudic I., Szekeres-BarthoJ., FatusicZ., Stray-Pedersen B., Dizdarevic-Hudic L., Latifagic A. et al. Dydrogesterone supplementation in women with threatened preterm delivery-the impact on cytokine profile, hormone profile, and progesterone-induced blocking factor. J. Reprod. Immunol. 2011; 92(1-2): 103-7.
  28. Brincat M.P., Baron Y.M. Dydrogesterone in reducing the risk of preterm birth. In: The 18th World Congress on Contraversies in Obstetrics, Gynecology & Infertility. Vienna, Austria, October 24-27, 2013.
  29. Приказ Министерства здравоохранения Российской Федерации от 07 ноября 2012 г. «Об утверждении стандарта специализированной медицинской помощи при преждевременных родах».
  30. Dodd J.M., Jones L., Flenady V., Cincotta R., Crowther C.A. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst. Rev. 2013; (7): CD004947.
  31. Siew J.Y.S. et al. Progestogen for threatened miscarriage: a randomized controlled trial comparing micronised progesterone and dydrogesterone. J. Maternal Fetal Neonatal Med. 2014; 27(Suppl.1): 243.
  32. Ashok V., Kumar R.M., Murali D., Arkendu Chatterjee. A review on vaginal route as a systemic drug delivery. Crit. Rev. Pharm. Sci. 2012; 1(1): 1-19.
  33. Neumann F., Dusterberg B. Entwicklung auf dem Gebiet der Gestagene. Reproduktionsmedizin. 1998; 14(2): 257-64.
  34. Itsekson A.M., Seidman D.S., Zolti M., Lazarov A., Carp H.J. Recurrent pregnancy loss and inappropriate local immune response to sex hormones. Am. J. Reprod. Immunol. 2007; 57(2): 160-5.
  35. Сидельникова В.М., Сухих Г.Т. Невынашивание беременности. Руководство для практикующих врачей. М.: МИА; 2010. 536 с.
  36. Schindler A.E., Campagnoli C., Druckmann R., Huber J., Pasqualini J.R., Schweppe K.W., Thijssen J.H. Classification and pharmacology of progestins. Maturitas. 2008; 61(1-2): 171-80.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015